Brief: Karyopharm Therapeutics Q4 Net Income USD -30.78 Million
19/02/2025 12:30
Feb 19 (Reuters) - Karyopharm Therapeutics Q4 operating expenses USD 61.823 million. * Q4 operating income USD -31.281 million * outlook FY revenue USD 140-155 million
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview